XERS
Xeris Biopharma·NASDAQ
--
--(--)
--
--(--)
5.54 / 10
Netural
Fund-flow data score 7.68/10, reflecting robust liquidity momentum with positive inflows across block, small, medium, and large orders. Analyst sentiment is overwhelmingly bullish (100% Strong Buy from one source), yet the historical win rate is only 50%. This combination suggests potential upside if momentum persists, but the mismatch between price trend and expectations adds uncertainty.
Fund Flow Rating
Analyst RatingStrong Buy
Wall Street Opinions
Strong Buy
Strong Buy
100%
Buy
0%
Hold
0%
Sell
0%
Strong Sell
0%
Date2026-01-09
InstitutionHC Wainwright & Co.
Times predicted2
Historical Win Rate50.0%
What is the analyst consensus for XERS?
- XERS holds a Bearish analyst rating, with 100% of experts assigning a Strong Buy grade. Factoring in net Outflows from order flow data, the comprehensive Sentiment Score stands at 5.54/10 (Netural).
